IQV - IQVIA Holdings Inc.
144.54 -0.45 (-0.31%)
After hours: 4:26PM EDT
| Previous close | 144.17 |
| Open | 143.97 |
| Bid | 144.85 x 800 |
| Ask | 144.85 x 800 |
| Day's range | 142.72 - 145.95 |
| 52-week range | 81.79 - 169.14 |
| Volume | 701,966 |
| Avg. volume | 1,249,877 |
| Market cap | 27.688B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | 133.39 |
| EPS (TTM) | 1.09 |
| Earnings date | 22 Jul 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 158.28 |
- Business Wire
IQVIA to Announce Second-Quarter Results on July 22, 2020
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), will announce its second-quarter financial results before the market opens on Wednesday, July 22, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
- Business Wire
IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their clinical trials will take place in premier investigative research centers with recognized professionals and with infrastructure focused on innovation and research development for patients.
- Business Wire
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Improves Oncology’s Standard of Care with Genomics Technology Collaboration
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its partnership with Thermo Fisher Scientific to use the Ion Torrent Genexus System, the first fully integrated, next-generation sequencing (NGS) platform, to deliver clinical trial lab results economically with unprecedented speed.
- Motley Fool
Forget IQVIA, Veeva Systems Is a Better Growth Stock
Here’s why Veeva Systems is the better choice for investors looking for exposure to companies performing clinical trial analytics.
- Zacks
Here's Why You Should Hold IQVIA Holdings (IQV) Stock Now
Solid technological suite and growth opportunities from emerging markets are positives for IQVIA Holdings (IQV). However, higher interest expense, seasonality and foreign exchange rate risks persist.
- Zacks
Why Is IQVIA (IQV) Up 2.6% Since Last Earnings Report?
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
IQVIA Launches the First Solution to Address the Unique Business and Compliance Needs of Healthcare Professionals as Part of Its OCE Suite
IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally.
- Business Wire
IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers
IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research, a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III randomized, double-blinded clinical study of preventive care for frontline healthcare workers fighting the COVID-19 pandemic.
- Zacks
Envestnet's (ENV) Q1 Earnings Beat Estimates, Improve Y/Y
Envestnet's (ENV) first- quarter 2020 earnings and revenues increase year over year.
- Zacks
Gartner (IT) Surpasses Q1 Earnings Estimates, Cuts View
Gartner (IT) first-quarter 2020 earnings and revenues increase year over year.
- Simply Wall St.
IQVIA Holdings Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a pretty great week for IQVIA Holdings Inc. (NYSE:IQV) shareholders, with its shares surging 11% to US$143...
- Business Wire
IQVIA Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor. This strategic alliance will examine the effectiveness of repurposed medicines, potential new drugs, and unlicensed therapies for treating COVID-19 patients.
- Motley Fool
IQVIA Holdings Inc. (IQV) Q1 2020 Earnings Call Transcript
With me on the call today are Ari Bousbib, Chairman and Chief Executive Officer; Michael McDonnell, Executive Vice President and Chief Financial Officer; Eric Sherbet, Executive Vice President and General Counsel; Nick Childs, Senior Vice President, Financial Planning and Analysis; and Jen Halchak, Senior Director, Investor Relations. Today, we will be referencing a presentation that will be visible during this call for those of you on our webcast.
- Business Wire
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
- Business Wire
IQVIA Launches Broad, Open COVID-19 Registry Platform to Advance Understanding, Collaboration, and Research
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com. The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatment outcomes.
- Business Wire
IQVIA Launches First Technology-Enabled COVID-19 Trial Matching Solution within the U.S. to Accelerate Treatment and Vaccine Development
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced its new technology-enabled COVID-19 Trial Matching Tool at c19trials.com, which is one of the world’s first online platforms that matches individuals with specific COVID-19 studies to accelerate clinical research projects.
- Business Wire
IQVIA Provides Update on Business Conditions in Light of COVID-19 and Provides Revised First-quarter 2020 Guidance; IQVIA will announce first-quarter results and update full-year 2020 guidance on April 28, 2020
IQVIA provides update on business conditions in light of COVID-19 and provides revised first-quarter 2020 guidance; releases Q1 earnings April 28th
- Simply Wall St.
When Should You Buy IQVIA Holdings Inc. (NYSE:IQV)?
IQVIA Holdings Inc. (NYSE:IQV) saw a significant share price rise of over 20% in the past couple of months on the...
- Business Wire
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Collaborates with University of Texas Medical Branch to Help Accelerate Development of COVID-19 Vaccines
Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its collaboration with the University of Texas Medical Branch (UTMB) to develop a novel assay for COVID-19 (SARS-CoV-2) tests, an essential tool for rapid development of a Coronavirus vaccine. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
- Simply Wall St.
Should You Worry About IQVIA Holdings Inc.'s (NYSE:IQV) CEO Salary Level?
Ari Bousbib has been the CEO of IQVIA Holdings Inc. (NYSE:IQV) since 2016. First, this article will compare CEO...
- Zacks
Stock Market News for Feb 13, 2020
Wall Street closed sharply higher on Wednesday as the number of new cases infected with coronavirus in China slowed down.
- Zacks
IQVIA (IQV) Surpasses Q4 Earnings and Revenue Estimates
IQVIA's (IQV) fourth-quarter 2019 earnings and revenues increase year over year.
- Zacks
IQVIA Holdings (IQV) Q4 Earnings and Revenues Surpass Estimates
IQVIA (IQV) delivered earnings and revenue surprises of 1.16% and 1.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
IQVIA (IQV) to Report Q4 Earnings: What's in the Cards?
IQVIA's (IQV) fourth-quarter 2019 earnings and revenues are likely to have increased year over year.
- Zacks
IQVIA Holdings (IQV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
IQVIA (IQV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
